In our study, the receipt of first-line chemotherapy, whether single-agent or multi-agent, which is a key component of the initial induction treatment for metastatic HER2-positive breast cancer, and the receipt of anti-HER2 therapy were identified as independent prognostic factors for overall survival (OS). The gene discussed is ERBB2; the disease is breast cancer.